Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0004352 (
autism
)
32,579
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Rett syndrome (RS) is an X-linked neurodevelopmental disorder and the second most common cause of genetic mental retardation in females. Different mutations in MECP2 are found in up to 95% of typical cases of RS. This mainly neuronal expressed gene functions as a major transcription repressor. Extensive studies on girls who have RS and mouse models are aimed at finding main gene targets for MeCP2 protein and defining neuropathologic changes caused by its defects. Studies comparing autistic features in RS with idiopathic
autism
and mentally retarded patients are presented. Decreased dendritic arborization is common to RS and
autism
, leading to further research on similarities in pathogenesis, including MeCP2 protein levels in autistic brains and MeCP2 effects on genes connected to
autism
, like
DLX5
and genes on 15q11-13 region. This area also is involved in Angelman syndrome, which has many similarities to RS. Despite these connections, MECP2 mutations in nonspecific autistic and mentally retarded populations are rare.
...
PMID:Rett syndrome. 1756 89
Mutations in MECP2 and Mecp2 (encoding methyl-CpG binding protein 2 [MeCP2]) cause distinct neurological phenotypes in humans and mice, respectively, but the molecular pathology is unclear. Recent literature claimed that the developmental homeobox gene
DLX5
is imprinted and that its imprinting status is modulated by MeCP2, leading to biallelic expression in Rett syndrome and twofold overexpression of Dlx5 and Dlx6 in Mecp2-null mice. The conclusion that
DLX5
is a direct target of MeCP2 has implications for research on the molecular bases of Rett syndrome,
autism
, and genomic imprinting. Attempting to replicate the reported data, we evaluated allele-specific expression of
DLX5
and DLX6 in mouse x human somatic cell hybrids, lymphoblastoid cell lines, and frontal cortex from controls and individuals with MECP2 mutations. We identified novel single-nucleotide polymorphisms in
DLX5
and DLX6, enabling the first imprinting studies of DLX6. We found that
DLX5
and DLX6 are biallelically expressed in somatic cell hybrids and in human cell lines and brain, with no differences between affected and control samples. We also determined expression levels of Dlx5 and Dlx6 in forebrain from seven male Mecp2-mutant mice and eight wild-type littermates by real-time quantitative reverse-transcriptase polymerase chain reaction assays. Expression of Dlx5 and Dlx6, as well as of the imprinted gene Peg3, in mouse forebrain was highly variable, with no consistent differences between Mecp2-null mutants and controls. We conclude that
DLX5
and DLX6 are not imprinted in humans and are not likely to be direct targets of MeCP2 modulation. In contrast, the imprinting status of PEG3 and PEG10 is maintained in MeCP2-deficient tissues. Our results confirm that MeCP2 plays no role in the maintenance of genomic imprinting and add PEG3 and PEG10 to the list of studied imprinted genes.
...
PMID:DLX5 and DLX6 expression is biallelic and not modulated by MeCP2 deficiency. 1770 95
DNA methylation in mammals has long been implicated in the epigenetic mechanism of parental imprinting, in which selective expression of one allele of specific genes is based on parental origin. Methyl CpG binding protein 2 (MeCP2) selectively binds to methylated DNA and mutations in the MECP2 cause the
autism
-spectrum neurodevelopmental disorder Rett syndrome. This review outlines the emerging story of how MeCP2 has been implicated in the regulation of specific imprinted genes and loci, including UBE3A and
DLX5
. The story of MeCP2 and parental imprinting has unfolded with some interesting but unexpected twists, revealing new insights on the function of MeCP2 in the process.
...
PMID:The Odyssey of MeCP2 and parental imprinting. 1796 11
Linkage analysis has reported the chromosomal region 7q21 to be related with
autism
. This region contains an imprinting region with MECP2-binding sites, and
DLX5
is reported to be modulated by MECP2.
DLX5
and adjacent DLX6 are homeobox genes working in neurogenesis. From these points,
DLX5
and DLX6 are candidate genes for
autism
. Therefore, we analyzed the expression of
DLX5
and DLX6, and also PEG10 as a control in the lymphoblasts of autistic spectrum disorder (ASD) patients by real-time PCR to identify potential abnormality of expression. And we also analyzed
DLX5
and DLX6 on ASD patients for mutation by direct sequence. The expression level of
DLX5
was not different between ASD and controls but was higher in four ASD patients compared to controls. Clinical features of these four patients were variable.
DLX5
expression was biallelic in two ASD patients and two controls, indicating that
DLX5
was not imprinted. There was no mutation in
DLX5
in ASD. Although
DLX5
was not likely to play major role in ASD, genes relating to
DLX5
expression and downstream of
DLX5
are considered to be candidate genes for some of the ASD patients. In DLX6, we detected a G656A base change (R219H) in two ASD patients who were male siblings. DLX6 may contribute to the pathogenesis of ASD.
...
PMID:Expression analysis and mutation detection of DLX5 and DLX6 in autism. 1919 2